Palisade Bio, Inc.
PALI · NASDAQ
Bulios Fair Price
$1.43
10.1% downside
Current Price
$1.59
According to Bulios Fair Price, PALI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Palisade Bio, Inc. (PALI) is a biotechnology company focused on the development of novel drugs and therapeutic approaches in the field of gastrointestinal diseases and rare metabolic disorders. The company is developing drugs and therapies that have the potential to alleviate health issues and improve the quality of life for patients suffering from these conditions. Palisade Bio emphasizes innovation and utilizes modern technologies and scientific knowledge to discover new treatment options. Their goal is to bring new drugs and therapies to the market that can make a real difference and enhance patient care. Palisade Bio is actively involved in research and clinical studies to confirm the effectiveness and safety of their products. Palisade Bio, Inc. (PALI) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focusing on innovative therapeutic approaches in the field of gastrointestinal diseases and rare metabolic disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
J. D. Finley
Employees
14
Headquarters
Denver
Upcoming events
Earnings
Upcoming earnings report